Alexander Cumbo - 02 Dec 2022 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: President and CEO, Director
Signature: /s/ David Tyronne Howton as attorney-in-fact for Alexander Cumbo
Issuer symbol: SLDB
Transactions as of: 02 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Dec 2022, 16:46:45 UTC
Previous filing: 13 Jun 2022
Next filing: 20 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Award		+584			584	02 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Stock Option (Right to Buy)	Award	$0	+228,900		$0.000000	228,900	02 Dec 2022	Common Stock	228,900	$6.77	Direct	F2
transaction	SLDB	Restricted Stock Units	Award	$0	+114,449		$0.000000	114,449	02 Dec 2022	Common Stock	114,449		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.
F2	This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.
F3	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
F4	The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.